AR and breast carcinoma: Previous studies have shown that approximately 50% of PD-L1 transmembrane proteins in breast cancer with androgen receptor (AR)-negative prevalence and TNBC cells express PD-L1, whose receptor is PD-1, and also bind PD-L2 as other ligands, and express CTLA-4.